- Home
- CJET vs ICU Comparison
CJET vs ICU Comparison
Compare CJET & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJET
- ICU
- Stock Information
- Founded
- CJET 2009
- ICU 2018
- Country
- CJET China
- ICU United States
- Employees
- CJET N/A
- ICU N/A
- Industry
- CJET Auto Manufacturing
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- CJET Consumer Discretionary
- ICU Health Care
- Exchange
- CJET Nasdaq
- ICU Nasdaq
- Market Cap
- CJET 12.2M
- ICU 10.4M
- IPO Year
- CJET N/A
- ICU N/A
- Fundamental
- Price
- CJET $1.82
- ICU $1.75
- Analyst Decision
- CJET
- ICU
- Analyst Count
- CJET 0
- ICU 0
- Target Price
- CJET N/A
- ICU N/A
- AVG Volume (30 Days)
- CJET 11.0K
- ICU 24.8K
- Earning Date
- CJET 03-04-2025
- ICU 04-15-2025
- Dividend Yield
- CJET N/A
- ICU N/A
- EPS Growth
- CJET N/A
- ICU N/A
- EPS
- CJET N/A
- ICU N/A
- Revenue
- CJET $10,275,000.00
- ICU $68,000.00
- Revenue This Year
- CJET N/A
- ICU N/A
- Revenue Next Year
- CJET N/A
- ICU $358.72
- P/E Ratio
- CJET N/A
- ICU N/A
- Revenue Growth
- CJET 31.31
- ICU N/A
- 52 Week Low
- CJET $1.50
- ICU $1.50
- 52 Week High
- CJET $23.94
- ICU $27.50
- Technical
- Relative Strength Index (RSI)
- CJET 52.26
- ICU 43.77
- Support Level
- CJET $1.78
- ICU $1.71
- Resistance Level
- CJET $1.84
- ICU $1.99
- Average True Range (ATR)
- CJET 0.10
- ICU 0.23
- MACD
- CJET 0.03
- ICU -0.00
- Stochastic Oscillator
- CJET 89.66
- ICU 2.94
About CJET Chijet Motor Company Inc.
Chijet Motor Co Inc is engaged in the research and development, production and sales of new energy vehicles. New energy vehicles refer to plug-in electric vehicles including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.